Stevanato Group Partners with Datwyler and LTS Device Technologies to Expand Self-Delivery Drug Solutions

Reuters

4 hours ago

Stevanato Group Partners with Datwyler and LTS Device Technologies to Expand Self-Delivery Drug Solutions

Stevanato Group S.p.A. has announced a collaboration with Datwyler and LTS Device Technologies to expand self-delivery options for large-volume drugs. This partnership aims to enable more convenient on-body delivery of high-dose therapies, such as anti-cancer treatments and monoclonal antibodies, by utilizing a pre-verified large-volume platform solution. The joint effort features Datwyler's NeoFlex™ plungers for larger volume containers, Stevanato Group's ready-to-use EZ-fill® cartridges, and LTS Device Technologies' Sorrel™ Platform, which is capable of delivering from 10 and 20mL cartridges. The collaboration is designed to accelerate time to market and support the shift from hospital to home administration of sensitive therapies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stevanato Group S.p.A. published the original content used to generate this news brief via PR Newswire (Ref. ID: EN64697) on January 16, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2603964177"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603964177\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603964177?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-16 18:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603964177","market":"nz","top_or_hot":-1,"title":"Stevanato Group Partners with Datwyler and LTS Device Technologies to Expand Self-Delivery Drug Solutions","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Stevanato Group Partners with Datwyler and LTS Device Technologies to Expand Self-Delivery Drug Solutions\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/STVN\">Stevanato Group S.p.A.</a> has announced a collaboration with Datwyler and LTS Device Technologies to expand self-delivery options for large-volume drugs. This partnership aims to enable more convenient on-body delivery of high-dose therapies, such as anti-cancer treatments and monoclonal antibodies, by utilizing a pre-verified large-volume platform solution. The joint effort features Datwyler's NeoFlex™ plungers for larger volume containers, Stevanato Group's ready-to-use EZ-fill® cartridges, and LTS Device Technologies' Sorrel™ Platform, which is capable of delivering from 10 and 20mL cartridges. The collaboration is designed to accelerate time to market and support the shift from hospital to home administration of sensitive therapies.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stevanato Group S.p.A. published the original content used to generate this news brief via PR Newswire (Ref. ID: EN64697) on January 16, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stevanato Group Partners with Datwyler and LTS Device Technologies to Expand Self-Delivery Drug Solutions</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStevanato Group Partners with Datwyler and LTS Device Technologies to Expand Self-Delivery Drug Solutions\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-16 18:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Stevanato Group Partners with Datwyler and LTS Device Technologies to Expand Self-Delivery Drug Solutions\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/STVN\">Stevanato Group S.p.A.</a> has announced a collaboration with Datwyler and LTS Device Technologies to expand self-delivery options for large-volume drugs. This partnership aims to enable more convenient on-body delivery of high-dose therapies, such as anti-cancer treatments and monoclonal antibodies, by utilizing a pre-verified large-volume platform solution. The joint effort features Datwyler's NeoFlex™ plungers for larger volume containers, Stevanato Group's ready-to-use EZ-fill® cartridges, and LTS Device Technologies' Sorrel™ Platform, which is capable of delivering from 10 and 20mL cartridges. The collaboration is designed to accelerate time to market and support the shift from hospital to home administration of sensitive therapies.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stevanato Group S.p.A. published the original content used to generate this news brief via PR Newswire (Ref. ID: EN64697) on January 16, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ESNT.UK","symbol_name":"ESSENTRA","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDL2xNlQ5:1","article_id":"2603964177","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603964177","pubTimestamp":1768557954,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Stevanato Group S.p.A. has announced a collaboration with Datwyler and LTS Device Technologies to expand self-delivery options for large-volume drugs. This partnership aims to enable more convenient on-body delivery of high-dose therapies, such as anti-cancer treatments and monoclonal antibodies, by utilizing a pre-verified large-volume platform solution. The joint effort features Datwyler's NeoFlex plungers for larger volume containers, Stevanato Group's ready-to-use EZ-fill cartridges, and LTS Device Technologies' Sorrel Platform, which is capable of delivering from 10 and 20mL cartridges. The collaboration is designed to accelerate time to market and support the shift from hospital to home administration of sensitive therapies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ESNT.UK":"ESSENTRA","STVN":"Stevanato Group S.p.A.","BK4121":"生命科学工具和服务","BK5031":"商品化工","BK4539":"次新股"},"translate_title":"Stevanato Group与Datwyler和LTS Device Technologies合作扩展自我递送药物解决方案","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ESNT.UK":0.9,"STVN":0.9},"content_text":"Stevanato Group Partners with Datwyler and LTS Device Technologies to Expand Self-Delivery Drug Solutions\n    \n\nStevanato Group S.p.A. has announced a collaboration with Datwyler and LTS Device Technologies to expand self-delivery options for large-volume drugs. This partnership aims to enable more convenient on-body delivery of high-dose therapies, such as anti-cancer treatments and monoclonal antibodies, by utilizing a pre-verified large-volume platform solution. The joint effort features Datwyler's NeoFlex™ plungers for larger volume containers, Stevanato Group's ready-to-use EZ-fill® cartridges, and LTS Device Technologies' Sorrel™ Platform, which is capable of delivering from 10 and 20mL cartridges. The collaboration is designed to accelerate time to market and support the shift from hospital to home administration of sensitive therapies.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stevanato Group S.p.A. published the original content used to generate this news brief via PR Newswire (Ref. ID: EN64697) on January 16, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}